Physician profile
Ali Masud
NPI 1952588535
$12,442.57
in general payments reported to CMS, 2019-2025
52 companies · $4,136 in 2025
The $4,136 reported for 2025 was more than what 80% of Interventional Cardiology providers received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,548 · 2020: $374 · 2021: $1,033 · 2022: $556 · 2023: $1,431 · 2024: $2,364 · 2025: $4,136.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,621 · Travel and Lodging: $1,310.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,621.45 |
| Travel and Lodging | $1,309.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $3,561.00 | 2021-2025 | Corevalve Evolut R, Symplicity G3, Linq II |
| Abiomed | $1,401.71 | 2019-2025 | Impella |
| Edwards Lifesciences Corporation | $1,273.53 | 2019-2025 | Sapien 3 Ultra Resilia |
| Novartis Pharmaceuticals Corporation | $985.05 | 2019-2025 | |
| Abbott Laboratories | $827.21 | 2023-2025 | Navitor, Mitraclip, Cardiomems |
| Amgen INC. | $570.88 | 2019-2025 | Repatha, Repatha |
| Canon Medical Systems USA, INC. | $563.25 | 2021 | |
| Boston Scientific Corporation | $321.65 | 2020-2025 | Watchman Flx, Watchman Access System, Bodyguardian |
| E.R. Squibb & Sons, L.L.C. | $269.28 | 2020-2025 | Eliquis, Camzyos |
| Biotronik INC. | $196.81 | 2019-2020 | |
| Pfizer INC. | $189.55 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $176.80 | 2019-2024 | Jardiance |
| Atricure, INC. | $172.21 | 2024-2025 | Synergy Ablation System |
| Baxter Healthcare | $168.06 | 2023-2024 | Hillrom - Carnation Ambulatory Monitor, Coseal |
| Merck Sharp & Dohme LLC | $144.10 | 2021-2025 | Verquvo, Capvaxive |
Show all 50 companies
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ali Masud listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.